ATOS logo

ATOSSA THERAPEUTICS INC

ATOSNASDAQ
🏆 #4783 by market capEarnings Nov 10US Equity
$1.97▼ $0.01 (−0.51%)
Market closed · at close
🔔
Track ATOS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.5%
7d▼ 11.7%
14d▼ 20.1%
30d▼ 21.5%
ytd▼ 77.5%
1y▼ 84.9%
🏦Market Cap
$20M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$1.95 – $2.00
52-Week Range
$1.70 – $19.35
Volume
$1.89B
Avg Volume
$1.54B
Shares Outstanding
10.0M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$442,024
P/E Ratio
-0.5
P/S Ratio
0.0x
EPS (TTM)
$-4.23
Dividend Yield
0.00%
Dilution (1yr)
+2.0%

Why Investors Own ATOS

  • ✓High-growth profile — revenue up +8.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 38% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ATOS logo

ATOSSA THERAPEUTICS INC

ATOS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$37M▲ +34.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$30M▲ +41.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.6M▲ +2.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$41M▼ −$30M YoY
StockOtter · stockotter.space

About ATOSSA THERAPEUTICS INC

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Ratings

ⓘ
Consensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
MarketWatch·2h ago

ATOSSA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift ATOS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

ATOSSA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.